Skip to main content
Fig. 4 | Critical Care

Fig. 4

From: Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia

Fig. 4

Inflammatory markers. Bars show the fold-change from baseline (log2) and pneumonia diagnosis among study groups at the diagnosis of pneumonia and treatment with antimicrobials timepoints. A IL-1β varied significantly among study groups (p = 0.025) and over time (p = 0.043). Post hoc comparisons confirmed that IL-1β was downregulated by MEM + AMK treatment at 48, 72, and 96 h compared with the CONTROL and MEM groups. B–D IL-6, IL-8, and IL-10 did not vary among study groups, but did show a downward trend over time. Post hoc analysis with Bonferroni correction: *p < 0.05 CONTROL versus MEM; †p < 0.05 CONTROL versus MEM + AMK; ‡p < 0.05 MEM versus MEM + AMK. Abbreviations: AMK, inhaled amikacin; CONTROL, control; IL, interleukin; MEM, IV meropenem

Back to article page

Critical Care

ISSN: 1364-8535